Display options
Share it on

World J Emerg Med. 2016;7(4):250-254. doi: 10.5847/wjem.j.1920-8642.2016.04.002.

Amiodaron in atrial fibrillation: post coronary artery bypass graft.

World journal of emergency medicine

Paria Habibollahi, Shahrzad Hashemi Jam, Samad Shams Vahdati, Hamidreza Morteza Baghi, Hassan Amiri

Affiliations

  1. Pharmacology and Toxicology Department, Tabriz University of Medical Science, Tabriz, Iran.
  2. Emergency Medicine Research Team, Emergency Department, Tabriz University of Medical Science, Tabriz, Iran.
  3. Emergency Department, Iran University of Medical Science, Tehran, Iran.

PMID: 27942340 PMCID: PMC5143307 DOI: 10.5847/wjem.j.1920-8642.2016.04.002

Abstract

BACKGROUND: Atrial fibrilation (AF) is the most common complication following heart surgeries; it often occurs in patients after coronary artery bypass graft (CABG). The purpose of this review is to categorize prophylaxes or treatment by administration of Amiodaron in patients with CABG.

DATA RESOURCES: We searched google scholar, pubmed, and Cochrane Library databases (the period 1970-2010) for articles on Amiodaron in CABG and cardiac surgery. A total of 1 561 articles were identified, and 30 articles met the criteria and were enrolled in this review.

RESULTS: Most studies supported Amiodarone for prophylaxi purpose in patients who were performed with CABG; few papers supported Amiodaron as a drug for treating CABG. The prophylaxis can decrease the incidence rate of AF in CABG, but if it uses as a treatment, the side effect of Amiodaron will decrease because all of the patients will not get Amiodarone. In the other hand use of Amiodarone as a treatment does not influence the length of hospital stay significantly but these kinds of study are so few.

CONCLUSION: No appropriate therapeutic method has been defined for AF. At present, the common way of treating AF following cardiac surgery is mainly based on prophylaxis in medical books and references.

Keywords: Lateral position; Pulmonary aspiration; Semi-lateral position

Conflict of interest statement

The authors declare that there is no conflict of interest.

References

  1. Circulation. 2000 Sep 19;102(12):1382-7 - PubMed
  2. Am J Cardiol. 1974 Aug;34(2):215-23 - PubMed
  3. Ann Thorac Surg. 2007 Apr;83(4):1326-31 - PubMed
  4. Circulation. 2002 Jul 2;106(1):75-80 - PubMed
  5. N Engl J Med. 1997 Dec 18;337(25):1785-91 - PubMed
  6. Am Heart J. 1999 Jul;138(1 Pt 1):144-50 - PubMed
  7. Lancet. 1994 Aug 20;344(8921):493-8 - PubMed
  8. J Am Coll Cardiol. 1999 Aug;34(2):343-7 - PubMed
  9. Ann Intern Med. 1992 Jul 15;117(2):141-50 - PubMed
  10. Am J Cardiol. 2000 Feb 15;85(4):462-5 - PubMed
  11. N Engl J Med. 1995 Jul 13;333(2):77-82 - PubMed
  12. Am Heart J. 1991 Jan;121(1 Pt 1):89-95 - PubMed
  13. Eur Heart J. 1996 Jul;17 Suppl C:41-7 - PubMed
  14. J Am Coll Cardiol. 1992 Jan;19(1):169-73 - PubMed
  15. Eur Heart J. 1994 Oct;15(10):1396-402 - PubMed
  16. N Engl J Med. 1994 Sep 22;331(12):785-91 - PubMed
  17. J Cardiovasc Thorac Res. 2012;4(1):17-20 - PubMed
  18. Eur Heart J. 2006 Jul;27(13):1584-91 - PubMed
  19. N Engl J Med. 1987 Feb 19;316(8):455-66 - PubMed
  20. Ann Thorac Surg. 2008 Jan;85(1):28-32 - PubMed
  21. J Am Coll Cardiol. 2005 May 17;45(10):1723-8 - PubMed
  22. Am J Cardiol. 1985 Mar 1;55(6):696-702 - PubMed
  23. Am J Cardiol. 1984 Jan 1;53(1):93-8 - PubMed
  24. Eur Heart J. 1983 Mar;4(3):180-5 - PubMed
  25. Am J Cardiol. 1983 Dec 1;52(10 ):1214-8 - PubMed
  26. Int J Cardiol. 1992 Apr;35(1):77-85 - PubMed
  27. Ann Thorac Surg. 2000 Jan;69(1):300-6 - PubMed
  28. Br Heart J. 1993 Jul;70(1):56-60 - PubMed

Publication Types